Kewaunee Scientific Corporation (KEQU) AI Stock Analysis

Founded in 1906 and headquartered in Statesville, North Carolina, Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through Domestic and International segments, delivering steel, wood, and laminate furniture alongside fume hoods, biological safety cabinets, laminar flow systems, moveable workstations, and epoxy resin worksurfaces. Its products support advanced research and critical operations across pharmaceuticals, biotechnology, education, healthcare, industrial manufacturing, and government sectors. The company distributes its solutions globally through dealers, subsidiaries, and a national distributor network.

Kewaunee expanded annual revenue from $168.9M in FY2022 to $219.5M in FY2023, $203.8M in FY2024, $240.5M in FY2025, and $282.0M in FY2026, achieving a five-year revenue compound annual growth rate of 13.8%. Gross margin rose from 14.3% in FY2022 to 28.5% in FY2026, while operating margin improved from -1.5% to 5.9%. Net income shifted from -$6.0M in FY2022 to a peak of $18.8M in FY2024 before settling at $9.6M in FY2026, with diluted EPS of $3.32. For the latest quarter ended July 31, 2026, revenue fell 6.7% year-over-year, while quarterly earnings dropped 44.2% year-over-year, bringing trailing twelve-month revenue to $277.2M and net margin to 3.0%.

As of July 31, 2026, Kewaunee Scientific held $8.2M in cash and short-term investments against total debt of $55.5M, resulting in net debt of $47.2M and total assets of $175.8M. Shareholders' equity was $75.0M, reflecting a debt-to-equity ratio of 0.74 and a current ratio of 2.20. In FY2026, operating cash flow reached $18.6M and free cash flow was $14.7M. Capital allocation in FY2026 included $3.9M in capital expenditures and $671,000 directed toward share buybacks.

With a market capitalization of $95.3M and an enterprise value of $121.2M, Kewaunee trades at a trailing price-to-earnings multiple of 11.9x and a forward multiple of 7.7x, both below the median of its US-listed Consumer Cyclical peers of 18.0x and 14.1x, respectively. Its enterprise value-to-EBITDA ratio of 5.5x also trades below the peer median of 11.1x, alongside a price-to-sales ratio of 0.3x versus the peer median of 0.7x. Over the past year, Kewaunee shares fell 22.5%, underperforming the 16.8% return of the S&P 500, though its five-year return of 149.5% outperformed the S&P 500 return of 83.0%.

Wall Street analysts tracking Kewaunee Scientific Corporation have established a mean price target of $28.00. This target implies an expected downside of -15.0% compared to the company's last close of $32.93 on October 16, 2026. Valuation metrics show a forward price-to-earnings multiple of 7.7x, compared with its trailing multiple of 11.9x and trailing earnings per share of $2.76. The company is scheduled to report its next earnings release on December 9, 2026.

This page is an AI-written research summary of Kewaunee Scientific Corporation (KEQU). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: KEQU income statement, KEQU balance sheet, KEQU key metrics, KEQU chart. See the KEQU stock overview for the latest quote and news.